Latest Regulatory Review News

Swoop Holdings confirms its support for Vonex Limited’s acquisition by Maxo Telecommunications, planning a full exit that frees capital for new growth opportunities.

Macarthur Minerals has updated the timetable for its pro-rata renounceable rights issue, providing shareholders with more time to participate in the A$2 million capital raise. The offer terms remain unchanged as the company awaits regulatory approval for a supplementary prospectus.

TPC Consolidated Limited has extended critical deadlines for its acquisition scheme with Wollar Solar Holding, awaiting Foreign Investment Review Board approval. The move delays the scheme's completion but keeps the deal alive for now.

The Takeovers Panel has declined to declare unacceptable circumstances in a dispute involving Mayfield Childcare Limited shareholders but has referred potential breaches of takeover laws to ASIC for further investigation.

Inventis Limited has requested a voluntary suspension of its shares on the ASX to finalize an important announcement following regulatory queries. The suspension will last until the announcement is released or trading resumes on 27 June 2025.

Alkane Resources has secured Swedish regulatory approval for its proposed merger with Mandalay Resources, advancing a significant consolidation in the gold and antimony mining sector. The deal now awaits further approvals before shareholder votes expected in July.

Yowie Group Ltd has formally applied to the Takeovers Panel for a review of its recent decision involving Keybridge Capital Limited, signaling ongoing regulatory scrutiny in this corporate governance matter.

Trading in Alphinity Global Equity Fund's Active ETF (XALG) has been temporarily halted, with personal trading also paused pending further announcements.

Radiopharm Theranostics has secured FDA Fast Track designation for RAD101, a novel imaging agent aimed at improving diagnosis of recurrent brain metastases. The move could speed development and regulatory review as the company advances its Phase 2 clinical trial.

Cyclopharm Limited has secured the maximum five-year U.S. patent extension for its flagship Technegas® Kit, extending market exclusivity to 2031 and reinforcing its strategic foothold in pulmonary imaging.

Firebrick Pharma has published its pivotal Phase 3 trial results for Nasodine nasal spray, confirming its effectiveness and safety in treating the common cold, especially when used early.

Clarity Pharmaceuticals reports that its Cu-SARTATE diagnostic agent significantly outperforms the current standard in detecting neuroendocrine tumours, paving the way for a pivotal Phase III study.